Today: 20 May 2026
Dow Jones today: Dow hovers near 49,000 as Fed decision and mega-cap earnings loom

Dow Jones today: Dow hovers near 49,000 as Fed decision and mega-cap earnings loom

NEW YORK, Jan 28, 2026, 10:26 (EST) — Regular session

  • Dow hovered near 49,000, showing little movement following a drop led by UnitedHealth on Tuesday
  • The S&P 500 briefly surged past 7,000, driven by strength in chip stocks.
  • Fed decision expected at 2 p.m. EST; Meta, Microsoft, Tesla, and IBM set to release earnings after the bell

The Dow Jones Industrial Average (.DJI) held steady on Wednesday morning, lingering near 49,000 as traders eyed the Federal Reserve and a flurry of late-day earnings reports from major companies. By 10:26 a.m. EST, the blue-chip index dipped 3.56 points, or 0.01%, to 48,999.85. Meanwhile, the S&P 500 inched up 0.16%, and the Nasdaq climbed 0.39%.

The Dow stumbled even as the S&P 500 briefly cleared 7,000—a milestone that’s taken on a life of its own as a trading cue. Chip stocks rallied, buoyed by upbeat reports from ASML and SK Hynix, sparking renewed hopes for AI-related spending. “These big round numbers can be difficult psychological tests for the market,” said Jeff Buchbinder, chief equity strategist at LPL Financial. Reuters

The Fed is set to release its policy decision at 2 p.m. EST, with Chair Jerome Powell scheduled to speak half an hour later. Markets are pricing in no change to interest rates, while investors look for clues in the Fed’s language, especially after officials’ forecasts revealed stark disagreements on whether and how many rate cuts might happen in 2026. “There is no urgency to lower rates aggressively,” noted Seema Shah, chief global strategist at Principal Asset Management. Reuters

Tuesday highlighted why the Dow often trails when tech leads the charge. The index dropped 0.83%, dragged down by UnitedHealth plunging 19.6% following a Medicare-related proposal that shook insurers and a gloomy 2026 revenue outlook. Humana slid 21%, while CVS Health dropped 14.2%. “There’s a little bit of a bifurcated market today,” said Phil Blancato, chief market strategist at Osaic Wealth. Reuters

UnitedHealth’s decline wiped out about 420 points from the Dow, according to Reuters calculations. Boeing also weighed on the index as investors digested its quarterly results.

Economic data gave reason for pause, but buyers kept pushing the rally. The Conference Board reported its consumer confidence index dropped 9.7 points in January, landing at 84.5—the lowest since 2014. Its expectations gauge also slipped further below levels that typically warn of recession risk.

Early Wednesday, individual stocks led the action while indexes stalled. Texas Instruments jumped following its forecast for first-quarter revenue and profit that topped estimates. Starbucks also climbed after reporting a stronger-than-expected rise in comparable sales. AT&T gained after projecting annual profit beyond forecasts, and GE Vernova rallied after raising its revenue outlook.

The Dow works differently. It’s price-weighted, so stocks with higher prices influence the index more than their market size might indicate. That means big moves in just one or two stocks can overwhelm what’s happening across the rest of the market.

The setup works both ways. Should Powell dampen expectations for rate cuts, or if early big tech earnings disappoint on AI investment, the Dow could quickly slide — especially with health insurers continuing to drop.

Traders will turn their attention later Wednesday to the Fed statement and Powell’s press conference. After the close, earnings reports from Meta, Microsoft, Tesla, and Dow component IBM are due.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Commvault stock steadies premarket after 31% wipeout on ARR worries
Previous Story

Commvault stock steadies premarket after 31% wipeout on ARR worries

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal
Next Story

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Go toTop